Клинический случай посвящен проблеме выбора препарата для проведения липидснижающей терапии у пациента с высоким риском развития фатальных сердечно-сосудистых осложнений.
Hypertension in Diabetes Study (HDS): I. Prevalence of hypertension in newly presenting type 2 diabetic patients and the association with risk factors for cardiovascular and diabetic complications. J Hypertens 1993; 11: 309–17.Diabetes mellitus a major risk factor for cardiovascular disease. A joint editorial statement by the American Diabetes Association; The National Heart Lung and Blood Institute; The Juvenile Diabetes Foundation International; The National Institute of Diabetes and Digestive and Kidney Diseases; and The American Heart Association. Circulation 1999; 100: 1132–3.Stamler J, Vaccaro O, Neaton J.D et al. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factors Intervention Trial. Diabetes Care 1993; 16: 434–44.Turner R.C, Millns H, Neil H.A et al. Risk factors for coronary artery disease in non - insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). BMJ 1998; 316: 823–8.Kothari V, Stevens R.J, Adler A.I et al. UKPDS 60: risk of stroke in type 2 diabetes estimated by the United Kingdom Prospective Diabetes Study risk engine. Stroke 2002; 33: 1776–81.Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian simvastatin Survival Study (4S). Lancet 1994; 344: 1389.Cholesterol and Recurrent Events (CARE) Investigators. Inflammation, pravastatin and the risk of coronary events after myocardial infarction in patient with average cholesterol levels. Circulation 1998; 98: 839–44.Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in ischemic Disease (LIPID) Study Group. N Eng J Med 1998; 339: 1349–57.West of Scotland Coronary Prevention Study Group. Influence of pravastatin and plasma lipids on clinical events in West of Scotland Coronary Prevention Study (WOSCOPS). Circulation 1998; 97: 1440–5.Downs J.R, Clearfield M, Weis S et al. Primery prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998; 279: 1615–22.Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol - lowering with simvastatin in 5963 people with diabetes: a randomized placebo - controlled trial. Lancet 2003; 361: 2005–16.Colhoun H.M, Betteridge D.J, Durrington P.N et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes study (CARDS): multicentre randomized placebo - controlled trial. Lancet 2004; 364: 685–96.European Gudelines on CVD prevention. Third joint European societies’ task force on cardiovascular disease prevention in clinical practice. Eur. Heart J 2003; 24: 1601–10.Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза. Российские рекомендации. ВНОК, 2005.Olsson A.G. Am. Heart J 2002; 144: 1044–51.Blasseto J.W. Am J Cardial 2003; 91(Suppl): 36–106.Jones P.H et al. for the STELLAR study group. Am J Cardiol 2003; 93: 152–60.Schuster H et al. for the MECURY I study group. Am Heart J 2004; 147: 705–12.Сусеков А.В. Программа клинических исследований розувастатина GALAXY. Сердце. 2005; 4, 4(22): 214–9.